Navigate to
-
High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...
-
Insert Link Medical Formulary Strategy ensures the most appropriate and clinically effective medical benefit drugs are evaluated with product-preferencing strategies, for all lines of business....
-
For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories
PA Sub-Categories: Specialty drugs Prime Article: Perspectives -
Medication Nonadherence Social Determinants of Health Risk Score: Development and Use 2024 AMCP Annual Posters Real-World First Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1...
-
Clinical deep dive Disease state overview WAS is a rare, X-linked, genetic disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmunity and...
-
May 22, 2025 – mepolizumab (Nucala) GlaxoSmithKline; an IL-5 antagonist monoclonal antibody New indication: add-on maintenance treatment of adults with inadequately controlled chronic obstructive...
-
All brand names are property of their respective owners. References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560...
-
Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...